These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22631070)

  • 1. Everolimus-induced lymphedema in a renal transplant recipient: a case report.
    Ersoy A; Koca N
    Exp Clin Transplant; 2012 Jun; 10(3):296-8. PubMed ID: 22631070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus-induced lymphoedema.
    Motse KG; Mashabane MJ
    S Afr Med J; 2016 Aug; 106(9):886-7. PubMed ID: 27601112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncontrast Magnetic Resonance Lymphangiography in a Rare Case of Everolimus-Related Lymphedema.
    Cellina M; Oliva G; Soresina M; Menozzi A; Boccanera D; Gibelli D
    Ann Plast Surg; 2020 Jan; 84(1):113-116. PubMed ID: 31663933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early everolimus-induced pneumonitis in a renal transplant recipient: A case report.
    Sułkowska K; Palczewski P; Miszewska-Szyszkowska D; Durlik M; Gołębiowski M; Małkowski P
    Ann Transplant; 2012 Dec; 17(4):144-8. PubMed ID: 23274336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of everolimus after kidney and hematopoietic stem cell transplantation.
    Keller F; Wiesner S; Bunjes D; Hartmann B; Schmitt M
    Ann Transplant; 2012 Dec; 17(4):52-8. PubMed ID: 23274324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphedema of the Transplanted Kidney and Abdominal Wall with Ipsilateral Pleural Effusion Following Kidney Biopsy in a Patient Treated with Sirolimus: A Case Report and Review of the Literature.
    Rashid-Farokhi F; Afshar H
    Am J Case Rep; 2017 Dec; 18():1370-1376. PubMed ID: 29269724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lymphedema in patients treated with sirolimus: 15 cases].
    Fourgeaud C; Simon L; Benoughidane B; Vignes S
    Rev Med Interne; 2019 Mar; 40(3):151-157. PubMed ID: 29752013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion therapy to everolimus in renal transplant recipients: results after one year.
    Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe everolimus-associated pneumonitis in a renal transplant recipient.
    Alexandru S; Ortiz A; Baldovi S; Milicua JM; Ruíz-Escribano E; Egido J; Plaza JJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3353-5. PubMed ID: 18658177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus: a review of its use in renal and cardiac transplantation.
    Dunn C; Croom KF
    Drugs; 2006; 66(4):547-70. PubMed ID: 16597167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDZ RAD. Rapamycin SDZ.
    Drugs R D; 1999 Jan; 1(1):97-9. PubMed ID: 10566000
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe sirolimus-induced acute hepatitis in a renal transplant recipient.
    Jacques J; Dickson Z; Carrier P; Essig M; Guillaudeau A; Lacour C; Bocquentin F; Aldigier JC; Rerolle JP
    Transpl Int; 2010 Sep; 23(9):967-70. PubMed ID: 20497403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
    Pascual J; Fernández AM; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii38-41. PubMed ID: 16815857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sirolimus-induced lymphedema in a kidney-transplant recipient: Partial recovery after changeover to tacrolimus].
    Al Gain M; Crickx B; Bejar C; Chen L; Azeroual L; Marinho E; Descamps V
    Ann Dermatol Venereol; 2015 May; 142(5):350-5. PubMed ID: 25683011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
    Kovarik JM; Kaplan B; Tedesco Silva H; Kahan BD; Dantal J; Vitko S; Boger R; Rordorf C
    Transplantation; 2002 Mar; 73(6):920-5. PubMed ID: 11923693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and treatment of lymphedema in heart transplant patients treated with everolimus.
    Ribezzo M; Boffini M; Ricci D; Barbero C; Bonato R; Attisani M; Pasero D; Rinaldi M
    Transplant Proc; 2014 Sep; 46(7):2334-8. PubMed ID: 25242782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.